Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease (LMD)

NCT03025256 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03025256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03025256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease (LMD)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 2, 2018
Completion date
June 1, 2027
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acral lentiginous melanoma, central nervous system melanoma, clinical stage iv cutaneous melanoma ajcc v8, leptomeningeal neoplasm, melanocytoma, metastatic lung non-small cell carcinoma, metastatic melanoma, metastatic mucosal melanoma, metastatic uveal melanoma, stage iv lung cancer ajcc v8